refractory, metastatic hormone-refractory Prostate cancer

DBCOND0025647Neoplasms Urogenital Diseases

refractory, metastatic hormone-refractory Prostate cancer is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as: Metastatic Hormone Refractory Prostate Cancer · Hormone-refractory prostate cancer metastatic
Classified under: Neoplasms
Urogenital Diseases
Indicated drugs: Docetaxel

Resolves to

Vocabularies

SNOMED CT427492003MedDRA10062904UMLSC1328504

What you can answer from here — as of October 24, 2026

1Indicated drugWith each drug's targets and mechanism

Listed above

1Structured indicationPopulation, line of therapy, route and combination as fields, not prose

3Clinical trialsPhase, status and sponsor resolved per trial

Which approved drugs for refractory, metastatic hormone-refractory Prostate cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account